An announcement from NRX Pharmaceuticals ( (NRXP) ) is now available.
Stephen Willard resigned abruptly as CEO of NRx Pharmaceuticals to lead a new biotech firm, with Dr. Jonathan Javitt taking over as Interim CEO. The company is actively seeking a new CEO with experience in commercial drug launches. At the Annual Meeting, stockholders elected Class III directors and approved the issuance of common stock, a potential reverse stock split, and the appointment of Salberg & Company, P.A. as independent auditors. These decisive moves aim to ensure the company’s robust governance and strategic financial maneuvering in the dynamic pharmaceutical industry.
For detailed information about NRXP stock, go to TipRanks’ Stock Analysis page.
